Strategies
SOL-AVAX L1 Pair Mean-Reversion on Hyperliquid 15-Minute (Short-Horizon Stat-Arb, Long-Short Cointegrated Pair)
Outcome: Abandoned
SolAvaxHyperliquidFifteenMinRatioZScorePairsMeanReversionLongShort
Outcome Summary
SolAvaxHyperliquidFifteenMinRatioZScorePairsMeanReversionLongShort proposed a clean, academically-grounded SOL/AVAX 15m stat-arb to fill four under-represented quotas at once, betting the two L1 peers' ratio would mean-revert intraday. But the base backtest failed on every axis: a decisively negative Sharpe of -3.30 with a fully-negative CI (the ratio did not reliably revert), only ~2.3 months of Hyperliquid 15m data, and degenerate economics with 162% impact cost against $38K capacity. It carried the same de-cointegrated/illiquid-pair signature as the abandoned SOL-AVAX, AAVE-COMP, and ETH/BTC pairs, compounded by 15m fee-fragility and the HL-15m data wall. The analyst abandoned it at the backtest-review gate, recommending the Research Lead stop proposing HL-15m and low-liquidity-alt-pair stat-arb until both sub-hourly data coverage and a genuinely cointegrated, liquid pair exist.
Hypothesis
Implementation
Market-neutral short-horizon stat-arb on the SOL/AVAX ratio on Hyperliquid perps, 15-minute bars. On each timestamp-aligned bar it commits the (SOL, AVAX) close pair to a SyncedBuffer, forms the SOL/AVAX ratio, and z-scores it over a 96-bar (24h) window. When z >= +2.0 it shorts SOL and longs AVAX (ratio rich); when z <= -2.0 it longs SOL and shorts AVAX, each leg at equal USD notional (delta-neutral). It closes both legs when the z-score reverts through the 0.3 exit band toward the mean or after a 96-bar time stop. Pure OHLCV, no supplementary data, leverage 1.0 with ~90% gross (45% per leg). Three edge parameters: lookback_bars, entry_z, exit_z.
Backtest Review
- Sharpe
- -3.30
- Total return
- -2.31%
- Max drawdown
- 6.31%
- Trades
- 60
- Win rate
- 51.7%
- Profit factor
- 0.79
Clean atomic two-leg pairs implementation; genuinely market-neutral intent (beta -0.03); academically-grounded mechanism class
Decisively negative edge in-window: Sharpe -3.30 with the ENTIRE CI negative (-5.47 to -0.75), PF 0.79, expectancy -$46/trade, PSR 0.0013; avg_loss $458 > avg_win $340, skew -3.39
Data-insufficient: only ~2.3 months of HL 15m data (2026-03-16 to 2026-05-24) — the same HL-15m wall that killed the prior SOL-HL-15m transplant; cannot support a valid walk-forward + holdout
Degenerate capacity/impact: capacity_usd $38K, impact_cost_pct 162% (impact exceeds gross PnL), commission 16.1% of gross — a 15m SOL/AVAX spread doesn't clear HL costs at any deployable size
SOL-AVAX pairs already shown to de-cointegrate / not reliably revert (abandoned in prior form)
Outcome Summary
15-minute cointegrated-pair mean-reversion on low-liquidity alt perps is triply blocked — the venue's sub-hourly history is too short to validate, the alt-pair ratio de-cointegrates rather than reverting, and the per-trade spread is far too small to survive fees plus market impact — so HL-15m and low-liquidity-alt-pair stat-arb should not be proposed until both sufficient data coverage and a genuinely cointegrated, liquid pair are confirmed.
The analyst abandoned it at the backtest-review gate before optimization because it failed on three fronts simultaneously: a decisively negative edge with a fully-negative CI (the SOL/AVAX ratio did not reliably revert, consistent with prior de-cointegration), data insufficiency (only ~2 months of Hyperliquid 15m history, the same wall that killed a prior SOL-HL-15m transplant), and degenerate economics (a 15m SOL/AVAX spread cannot clear HL fees and 162% market impact at $38K capacity).
A market-neutral, OHLCV-only short-horizon stat-arb on the SOL/AVAX ratio using 15-minute Hyperliquid perps — z-scoring the ratio over a 96-bar (24h) window and taking dollar-neutral pair positions on ±2σ reversion (short SOL/long AVAX when the ratio was rich, the inverse when cheap), exiting near the mean or on a time stop, with 3 parameters, to fill the Hyperliquid, short-horizon, long/short, and pairs quotas at once.
Over ~2.3 months of available data (2026-03-16 to 2026-05-24) the cointegrated build was genuinely market-neutral (beta -0.03) but had a decisively negative edge: -2.3% return (CAGR -9.6%), Sharpe -3.30 with the entire CI negative (-5.47 to -0.75), profit factor 0.79, per-trade expectancy -$46, PSR 0.0013, and avg loss ($458) larger than avg win ($340) with skew -3.39. Capacity was just $38K with impact cost at 162% of gross PnL and commission 16.1% of gross.
Backtest and paper results are hypothetical. Trading involves risk of loss.